Arzneimittel, welche von Swissmedic im Rahmen der Access Consortium New Active Substance Work Sharing Initiative (NASWSI) zugelassen wurden:
| Arzneimittel | Wirkstoff | Beteiligte Behörden | Weiterführende Links |
|---|---|---|---|
| Xofluza® | Baloxavir Marboxil | Australia’s Therapeutic Goods Administration (TGA), Health Canada | Swissmedic lässt erstmals eine neue aktive Substanz (NAS) im Rahmen des ACSS Consortiums zu |
| Kesimpta® | Ofatumumab | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore | Swissmedic lässt erneut ein Arzneimittel im Rahmen des Access Consortiums zu |
| VeraSeal® | Fibrinogen und Thrombin | Australia’s Therapeutic Goods Administration (TGA), Health Canada | |
| Verquvo® | Vericiguat | Australia’s Therapeutic Goods Administration (TGA), Health Sciences Authority (HSA) Singapore | |
| Kerendia® | Finerenone | Health Sciences Authority (HSA) Singapore, Australia’s Therapeutic Goods Administration (TGA) | |
| Nexviadyme® | Avalglucosidase alfa | Health Canada, Australia’s Therapeutic Goods Administration (TGA) | |
| Cibinqo® | Abrocitinib | Health Sciences Authority (HSA) Singapore | |
| Vabysmo® | Faricimab | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA) | Internationale Zusammenarbeit im Heilmittelbereich |
| Scemblix® | Asciminib | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA) | |
| Kapruvia® | Difelikefalin | Australia’s Therapeutic Goods Administration (TGA), Health Canada | |
| Mounjaro® | Tirzepatid | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore | |
| Tavneos® | Avacopan | Health Canada | |
| Vafseo® | Vadadustat | Australia’s Therapeutic Goods Administration (TGA), Medicines and Healthcare Products Regulatory Agency (MHRA) | |
| Alhemo® | Concizumab | Australia’s Therapeutic Goods Administration (TGA), Health Canada | |
| Omvoh® | Mirikizumab | Australia’s Therapeutic Goods Administration (TGA) | |
| Veoza® | Fezolinetant | Australia’s Therapeutic Goods Administration (TGA) | |
| Awiqli® | Insulin icodec | Health Canada, Australia’s Therapeutic Goods Administration (TGA) | |
| Fruzaqla® | Fruquintinib | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA) | |
| Velsipity® | Etrasimod | Health Sciences Authority (HSA) Singapore | |
| Winrevair® | Sotatercept | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Health Sciences Authority (HSA) Singapore | |
| Andembry® | Garadacimab | Australia’s Therapeutic Goods Administration (TGA), Health Canada, Medicines and Healthcare Products Regulatory Agency (MHRA) | |
| Rystiggo® | Rozanolixizumab | Australia’s Therapeutic Goods Administration (TGA), Health Canada | |
| Vyloy® | Zolbetuximab | Australia’s Therapeutic Goods Administration (TGA), Health Sciences Authority (HSA) Singapore | |
| Hympavzi® | Marstacimab | Australia’s Therapeutic Goods Administration (TGA), Health Sciences Authority (HSA) Singapore | |
| Nemluvio® | Nemolizumab | Australia’s Therapeutic Goods Administration (TGA), Health Sciences Authority (HSA) Singapore, Medicines and Healthcare Products Regulatory Agency (MHRA) |
Arzneimittel, welche von Swissmedic im Rahmen der Access Consortium Generic Medicines Work Sharing Initiative (GMWSI) zugelassen wurden:
| Arzneimittel | Wirkstoff | Beteiligte Behörden | Weiterführende Links |
|---|---|---|---|
| Everolimus Teva® | Everolimus | Australia’s Therapeutic Goods Administration (TGA), Health Canada | |
| Dabigatran Sandoz® | Dabigatran | Australia’s Therapeutic Goods Administration (TGA) | |
| Agilus® | Dantrolen | Medicines and Healthcare Products Regulatory Agency (MHRA) | |
| Enzalutamid Sandoz® | Enzalutamid | Medicines and Healthcare Products Regulatory Agency (MHRA) |
Arzneimittel, welche von Swissmedic im Rahmen der Access Consortium Biosimilar Medicines Work Sharing Initiative (BSWSI) zugelassen wurden:
| Arzneimittel | Wirkstoff | Beteiligte Behörden | Weiterführende Links |
|---|---|---|---|
| Obodence® | Denosumab | Medicines and Healthcare Products Regulatory Agency (MHRA) |
Letzte Änderung 05.05.2025